Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

Fig. 2

Pharmacodynamic differences on B cells between ADA + and ADA- patients at 6 months follow-up. a Percentage CD19 + cells in the peripheral blood 6 months after rituximab infusion, showing significantly higher values in all ADA positive patients compared to ADA negative patients (p = 0.002). Red line shows the group median. b ADA-positive patients have a significantly higher median value of CD19 + cells in the peripheral blood expressed as absolute numbers per microliter (p = 0.003). Red line shows group median. c Correlation (Spearman rho) between the titers of ADA (expressed as AU/mL) and the peripheral B cell count at 6 months follow up (expressed as CD19%) did not show any correlation (p = 0.43, r =  − 0.2 95%CI − 0.63–0.32). d At 6 months after rituximab infusion, no statistically different rate of achievement of B cell depletion was seen between ADA-positive and ADA-negative groups; B cell depletion (BCD) defined as peripheral blood CD19% < 0.5. e At 6 months after rituximab infusion, ADA positive were stratified into either higher ADA titre (above 5 AU/mL) and lower ADA titre (lower or equal to 4 AU/mL) and show no statistically different rate of achievement of BCD. f No difference was observed when comparing rates of BCD between ADA negative and high ADA positive (above 5 AU/mL)

Back to article page